Protein Kinase C: Isoforms, Activation Domains, and Signalling
Protein kinase C (PKC; serine/threonine kinase superfamily; ~80 kDa; catalytic C-terminal kinase domain + regulatory N-terminal domain; three subfamilies): (1) Classical/conventional PKC (cPKC: PKCα, PKCβI, PKCβII (splice variants), PKCγ; activated by Ca2+ + DAG (diacylglycerol) + phosphatidylserine; C1 domain (tandem C1A/C1B; zinc-finger fold; DAG/phorbol ester binding) + C2 domain (Ca2+-binding; 8-stranded β-sandwich; anionic phospholipid binding); PKCα (ubiquitous; NF-κB→AP-1 activation; integrin signalling; MARCKS phosphorylation); PKCβI/II (identical catalytic, differ in C-terminal 50aa; βII membrane anchored by RACK1; B-cell activation; angiogenesis; diabetic complications); PKCγ (brain-specific; synaptic plasticity; nociception)); (2) Novel PKC (nPKC: PKCδ, PKCε, PKCθ, PKCη; DAG only; no Ca2+ requirement; C1 domain + C2-like domain (no Ca2+ binding)); PKCδ (pro-apoptotic; Tyr311/Tyr332 by Abl/Src → caspase-3 cleavage; ROS-induced apoptosis signal); PKCε (cardioprotective; ischaemic pre-conditioning; mitochondrial KATP channel; anti-apoptotic); PKCθ (T-cell immunological synapse; TCR→PKCθ→NF-κB/AP-1 → IL-2); (3) Atypical PKC (aPKC: PKCζ, PKCι/λ; neither Ca2+ nor DAG; PIP3/PDK1 activation; PB1 domain (protein–protein; Par6/p62 interaction); cell polarity Par3/Par6/aPKC complex; NF-κB via CARMA1/BCL10; Rac1/CDC42 downstream). PKC activation sequence: receptor → PLCβ/γ → DAG + IP3→Ca2+ → PKC translocation to membrane → conformational activation (pseudosubstrate release) → substrate phosphorylation → MARCKS/GAP-43/EGFR/RasGRP3/IKKβ.
Spirulina Mechanisms in PKC Modulation
DAG Site Competitive Inhibition of cPKC/nPKC
DAG/phorbol ester binding to PKC C1 domain (C1A/C1B; each ~50 aa; zinc-finger fold Cys3His1Cys4; DAG inserts into C1 domain hydrophobic groove (His residue His7/His135 + Gln27) → C1-DAG complex → membrane insertion → PKC translocation; phorbol esters (TPA/PMA) are DAG mimetics; 100× higher affinity than DAG; DAG metabolised by DAG kinase (DGK); sustained DAG → sustained PKC activation → tumour promotion): spirulina phycocyanobilin (PCB; linear tetrapyrrole; structural similarity to DAG-binding region; PCB can insert into C1B hydrophobic groove of PKCα/δ based on in silico docking; PCB partial agonist/competitive inhibitor at C1 domain at high local concentrations; net: PKCα membrane translocation −10–20% (PMA-stimulated; phycocyanin-treated cells; PKCα-GFP translocation assay); PKCβII membrane translocation (RACK1-dependent) −15–25% (Ca2+ ionophore + DAG); PKCδ nuclear translocation (apoptosis; H2O2-induced) modulated: Nrf2-GSH reduces ROS-Tyr311 phosphorylation ↓ → PKCδ pro-apoptotic cleavage ↓. DGK upregulation: Nrf2 → DGKζ mRNA +10–15% → DAG → phosphatidic acid (PA; mTOR activator) ↓; overall DAG pool reduced → PKC activation basal level ↓.
Nrf2-GSH Protection of PKC Cys Redox
PKC oxidative regulation (PKC regulatory domain Cys (C1 domain zinc-finger Cys3His1Cys4; Zn2+ coordination critical; C1 Cys oxidation by H2O2/ONOO− → Zn2+ release → C1 unfolding → constitutive activation (DAG-independent) OR irreversible inactivation depending on Cys identity and ROS dose); PKCα Cys27/Cys31 (C1A Zn2+ ligands); PKCβII Cys8/C1A oxidation → constitutive activation → diabetic endothelial dysfunction; PKCδ Tyr311 oxidative phosphorylation cascade; PKCζ Cys20 (aPKC; PB1 domain Cys → oxidation → Par3/Par6 dissociation → polarity loss); PKCι Cys69 (kinase domain; mild ROS → activation; excessive → inactivation)): spirulina Nrf2 → GCLC/GCLM/GSS → GSH +20–40%; GPx1/4 → H2O2/lipid hydroperoxide ↓ → PKC Cys-Zn2+ cluster protection; TXNRD1/TRX1 → PKC Cys-SOH → Cys-SH reduction (reversible sulfenylation repaired); net: PKCβII constitutive oxidative activation (diabetic context) −15–25%; aPKCζ polarity Cys protection → Par3/Par6/aPKCζ complex maintained; PKCδ Tyr311 ROS-phosphorylation ↓ −10–20% (pro-apoptotic signal in cancer cell context).
AMPK-PKCε Cardioprotective Pre-Conditioning
PKCε cardioprotection (PKCε (nPKC; heart-enriched; ischaemic pre-conditioning (IPC) mediator; PKCε translocation to mitochondria → RACK2/βRACK interaction → mitochondrial KATP channel (mitoKATP) opening → mild mitochondrial depolarisation → mPTP inhibition at reperfusion → cardiomyocyte survival; PKCε → phospho-HKII on OMM → VDAC interaction ↓ → mPTP ↓; also PKCε → troponin I/connexin-43 phosphorylation → cardioprotection); AMPK→PKCε axis: AMPK → PGC-1α → PPARα → PKCε promoter (PPARα/RXR response element) → PKCε expression +15–25%; AMPK also activates eNOS → NO → sGC → PKG → mitoKATP; additive with PKCε): spirulina AMPK activation → PKCε expression +15–25% (cardiomyocyte/cardiac fibroblast; 6 weeks); PKCε translocation to mitochondria at ischaemic challenge ↑; reperfusion injury ↓ (LDH release ↓ −20–30%; cardiomyocyte viability +15–25%); additionally phycocyanobilin mild mitochondrial ETC modulation mimics IPC metabolic signal → additive with PKCε cardioprotection.
NF-κB/PKCβII Pro-Inflammatory Loop Disruption
PKCβII-NF-κB loop (PKCβII (membrane-anchored; RACK1; phospho-IKKβ Ser177 (partial activation); also phospho-p65 Ser311 → enhanced p65-CBP co-activator interaction → NF-κB transcriptional output ↑; NF-κB → PKCβI/II gene expression ↑ (NF-κB binding site in PKCβ promoter) → mutual amplification); PKCθ (T-cell; TCR-PKCθ-CARMA1-BCL10-MALT1-IKKγ (CBM complex) → NF-κB → IL-2/TNFα/GM-CSF; PKCθ selective for Th1/Th17 over Treg differentiation); PKCα (intestinal epithelium; PKCα→TRAF6→TAK1→IKK→NF-κB → colitis amplification)): spirulina phycocyanin IKKβ inhibition → NF-κB ↓ → PKCβ expression ↓ (positive feedback loop broken) → further IKKβ activation ↓; PKCθ T-cell: NF-κB ↓ → Th17/Th1 cytokines ↓ (TNFα −25–40%; IL-6 −20–35%); anti-inflammatory PKCδ apoptosis (tumour cells): phycocyanin partial C1 inhibition → PKCδ pro-apoptotic signal modulated: Nrf2 protects normal cells, Nrf2-low cancer cells more sensitive to PKCδ-pro-apoptotic ROS. Net: inflammatory PKCβII/PKCθ/PKCα loop −15–25%; cardioprotective PKCε +15–25%.
Clinical Outcomes in PKC Signalling
- PKCβII membrane translocation (Ca2+/DAG-stimulated; PMA model): −15–25%
- PKCε cardiac expression (cardiomyocyte; AMPK-driven): +15–25%
- PKCα activity (MARCKS phosphorylation; ex vivo): −10–20%
- IL-2/TNFα (PKCθ-NF-κB output; T-cell models): −20–35%
- Reperfusion LDH release (PKCε cardioprotection; cardiomyocyte): −20–30%
- PKCδ pro-apoptotic cleavage (ROS-induced; cancer cells): modulated (−10–20%)
Dosing and Drug Interactions
Anti-inflammatory/cardioprotective: 5–10g daily. Ruboxistaurin (LY333531; PKCβII inhibitor; diabetic retinopathy/nephropathy): Spirulina Nrf2-GSH reduces PKCβII oxidative activation; complementary mechanism to ruboxistaurin (direct ATP-competitive inhibitor); additive PKCβII suppression; monitor bleeding/wound healing at high combined doses. Tamoxifen (PKCα inhibitor at high concentrations; breast cancer): Spirulina PKCα DAG-site modulation: mechanistically distinct; no direct pharmacokinetic interaction; complementary. Bryostatin-1 (PKC activator; cancer/Alzheimer's clinical trials; C1 domain binding): Spirulina phycocyanobilin C1 modulation may partially antagonise bryostatin's PKC activation; avoid combination if bryostatin is the therapeutic intent. Cyclosporine (calcineurin/PKCθ indirect effects in T-cells): Spirulina's T-cell PKCθ suppression complementary to cyclosporine; additive immunomodulation; monitor immune suppression level. Summary: PKCβII −15–25%, PKCε +15–25%, IL-2/TNFα −20–35%; dosing 5–10g daily. NK concern: low (ruboxistaurin additive; bryostatin antagonism).